Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Nico Gagelmann, Kyle Hebert, Thomas McGovern, Gabrielle Schmidt, Valerie Stewart, Donna Neuberg, Stephen Spellman, Jeffery Auletta, Steven Devine, Robert Soiffer, Immaculata De Vivo, Christopher Reilly, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 373.

https://doi.org/10.1182/blood-2025-373

Published: 2025

Journal Articles

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Blood (2025) 146 (Supplement 1): 1949.

https://doi.org/10.1182/blood-2025-1949

Published: 2025

Journal Articles

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Blood (2025) 146 (Supplement 1): 4583.

https://doi.org/10.1182/blood-2025-4583

Published: 2025

Journal Articles

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

Blood (2025) 146 (Supplement 1): 4590.

https://doi.org/10.1182/blood-2025-4590

Published: 2025

Journal Articles

An integrative prognostic model for transplant outcomes in myelofibrosis

Blood (2025) 146 (Supplement 1): 912.

https://doi.org/10.1182/blood-2025-912

Published: 2025

Journal Articles

Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial

Blood (2025) 146 (Supplement 1): 911.

https://doi.org/10.1182/blood-2025-911

Published: 2025

Journal Articles

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Blood (2025) 146 (Supplement 1): 171.

https://doi.org/10.1182/blood-2025-171

Published: 2025

Journal Articles

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Blood (2025) 146 (17): 2063–2072.

https://doi.org/10.1182/blood.2025029773

Published: 2025

Includes: Supplemental data

Journal Articles

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Blood (2025) 146 (14): 1677–1686.

https://doi.org/10.1182/blood.2025028330

Published: 2025

Includes: Supplemental data

Journal Articles

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C. P. Cross, Joanna Drozd-Sokolowska, Vaneuza Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire Harrison, Gabriela Hobbs, Tania Jain, Joseph D. Khoury, Jean Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel H. Wiseman, Ibrahim Yakoub-Agha, Donal P. McLornan

Blood (2025) 145 (22): 2561–2573.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

Blood (2025) 145 (18): 1987–2001.

https://doi.org/10.1182/blood.2024025131

Published: 2025

Includes: Supplemental data

Journal Articles

GSI: myeloma—cold case closed?

Maximilian Merz, Nico Gagelmann

Blood (2025) 145 (2): 148–149.

https://doi.org/10.1182/blood.2024027056

Published: 2025

Journal Articles

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

Normann Steiner, Evgeny Klyuchnikov, Anita Badbaran, Radwan Massoud, Gabriele Zeck, David Nachbaur, Dominik Wolf, Nico Gagelmann, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3571.

https://doi.org/10.1182/blood-2024-205849

Published: 2024

Journal Articles

CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

Blood (2024) 144 (Supplement 1): 2073.

https://doi.org/10.1182/blood-2024-205103

Published: 2024

Journal Articles

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Luca Lanino, Anthony M. Hunter, Nico Gagelmann, Marie Robin, Claudia Sala, Daniele Dall'Olio, Carmelo Gurnari, Lorenzo Dall'Olio, Yu-Hung Wang, Lisa Pleyer, Blanca Xicoy, Guillermo Montalban-Bravo, Lee-Yung Shih, Tamanna Haque, Omar Abdel-Wahab, Klaus Geissler, Alex Bataller, Alexandre Bazinet, Manja Meggendorfer, Ilaria Carola Casetti, Elisabetta Sauta, Erica Travaglino, Laura Palomo, Lurdes Zamora, David Quintela, Andres Jerez, Elena Cornejo, Paloma Garcia Martin, Marina Díaz-Beyá, Alejandro Avendaño Pita, Veronica Roldan, Dolly Viviana Fiallo Suarez, Estefania Cerezo Velasco, Marisa Calabuig, Esperanza Such, Guillermo Sanz, Anne Sophie Kubasch, Cristina Castilla-Llorente, Claude-Éric Bulabois, Laetitia Souchet, Hussein Awada, Massimo Bernardi, Patrizia Chiusolo, Antonio Curti, Luisa Giaccone, Francesco Onida, Lorenza Maria Borin, Francesco Passamonti, Elisa Diral, Vladan Vucinic, Gregorio Maria Bergonzi, Maria Teresa Voso, Hsin-An Hou, Wen-Chien Chou, Chi-Yuan Yao, Chien-Chin Lin, Hwei-Fang Tien, Alessia Campagna, Marta Ubezio, Antonio Russo, Gabriele Todisco, Giulia Maggioni, Cristina Astrid Tentori, Alessandro Buizza, Gianluca Asti, Matteo Zampini, Elena Riva, Mattia Delleani, Angela Consagra, Francesca Ficara, Armando Santoro, Luciana Carota, Tiziana Sanavia, Cesare Rollo, Ahmad Kiwan, Jennifer VanOudenhove, Piero Fariselli, Najla H. Al Ali, David Sallman, Wolfgang Kern, Guillermo Garcia-Manero, Swapna Thota, Elizabeth A. Griffiths, Matilde Yung Follo, Carlo Finelli, Uwe Platzbecker, Francesc Sole, Maria Diez-Campelo, Jaroslaw Maciejewski, Rafael Bejar, Felicitas R. Thol, Nicolaus Kröger, Pierre Fenaux, Raphael Itzykson, Timothy Aaron Graubert, Michaela Fontenay, Amer M. Zeidan, Rami S. Komrokji, Valeria Santini, Torsten Haferlach, Ulrich Germing, Saverio D'Amico, Gastone Castellani, Mrinal M. Patnaik, Eric Solary, Eric Padron, Matteo Giovanni Della Porta

Blood (2024) 144 (Supplement 1): 1003.

https://doi.org/10.1182/blood-2024-200104

Published: 2024

Journal Articles

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Blood (2024) 144 (Supplement 1): 2007.

https://doi.org/10.1182/blood-2024-210451

Published: 2024

Journal Articles

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2024-211410

Published: 2024

Journal Articles

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Radwan Massoud, Margherita Ursi, Francesco Barbato, Francesco De Felice, Enrico Maffini, Marcello Roberto, Evgeny Klyuchnikov, Claudia Langebrake, Nico Gagelmann, Gabriele Zeck, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Francis A. Ayuk, Nicolaus Kroeger, Francesca Bonifazi

Blood (2024) 144 (Supplement 1): 7374.

https://doi.org/10.1182/blood-2024-211102

Published: 2024

Journal Articles

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Kristin Rathje, Kordelia Barbullushi, Nico Gagelmann, Anita Badbaran, Johanna Richter, Mathias Schäfersküpper, Franziska Elisabeth Marquard, Radwan Massoud, Sofia Oechsler, Evgeny Klyuchnikov, Ina Rudolph, Silke Heidenreich, Christian Niederwieser, Catherina Lück, Dietlinde Janson, Christine Wolschke, Boris Fehse, Francis A. Ayuk, Nicolaus Kroeger

Blood (2024) 144 (Supplement 1): 3547.

https://doi.org/10.1182/blood-2024-207569

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Longer telomeres in donors aged ≥35 years reduce graft failure and non-relapse mortality after allogeneic HCT

Impact of bridging therapy on efficacy of CD19 CAR T cell therapy in diffuse-large B cell lymphoma: Histology and the choice of drug matter

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

CAR T-cells or bispecific antibodies for relapsed/refractory multiple myeloma: Head-to-head real-world european comparison

An integrative prognostic model for transplant outcomes in myelofibrosis

Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective multicenter phase II trial

Matched unrelated vs. Haploidentical donor for allogeneic stem cell transplantation in patients with acute leukemia with identical GvHD prophylaxis – a randomized prospective european trial.

Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy

Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma: a registry analysis from the DRST

Role of allo-HCT in “nonclassical” MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT

GSI: myeloma—cold case closed?

Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission

CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis

A Molecular-Based Ecosystem to Improve Personalized Medicine in Patients with Chronic Myelomonocytic Leukemia (CMML)

Efficacy of Anti-BCMA CAR-T Cell Therapies in Multiple Myeloma Patients with Prior Exposure to Bispecific Antibodies- Results from a Retrospective Multi-Center Registry Analysis

Cilta-Cel Is Associated with Improved Outcomes and Distinct Cellular Dynamics Compared with Ide-Cel for Relapsed or Refractory Multiple Myeloma

The Impact of the Absolute Lymphocyte Count before Anti-T-Lymphocyte Globulin (ATLG) Administration on Transplant Outcomes in Matched Unrelated Peripheral Blood Stem Cell Allogeneic Stem Cell Transplantation

Early Tapering of Immunosuppression in MRD Positive Myelofibrosis Patients Induces Molecular Response and Excellent Outcome after Hematopoietic Stem Cell Transplantation

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only